Latest News

When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 23x, you may consider Sun...

Marsh & McLennan Companies (MRSH) has wrapped up FY 2025 with fourth quarter revenue of US$6.6b and basic EPS of US$1.69, alongside net income of US$821m, while the trailing twelve months show revenue of US$27.0b and EPS of US$8.47 anchoring the full year picture. The company has seen quarterly revenue move from US$6.1b in Q4 2024 to US$6.6b in Q4 2025, with basic EPS in those periods at US$1.60 and US$1.69 respectively, presenting a set of results where solid top line scale is paired with...

Texas Capital Bancshares (TCBI) is back in focus after a strong fourth quarter and full year 2025, where earnings and revenue topped market expectations and management issued upbeat 2026 guidance. See our latest analysis for Texas Capital Bancshares. That upbeat earnings report, new 2026 guidance and a refreshed buyback plan have arrived alongside a 30 day share price return of 9.91% and a 90 day share price return of 20.50%, while the 1 year total shareholder return of 27.40% points to...

If you are wondering whether Aon shares at around US$342.95 still make sense for your portfolio, the key question is how that price lines up with the underlying value of the business. The stock has had mixed returns, with a 2.1% gain over the past week but a 3.8% decline over the last month and a 7.1% decline over the past year, which can change how investors view its growth potential and risk profile. Recent news coverage has largely focused on Aon's position as a major global insurance...

Multiple securities fraud class action lawsuits have been filed against Klarna Group (NYSE:KLAR). The suits allege material misstatements in Klarna’s IPO documents regarding risks tied to buy now, pay later loss reserves. Claims focus on disclosures around underwriting practices and credit loss reserves at the time of the IPO. Klarna Group, trading on the NYSE under the ticker NYSE:KLAR, last closed at $24.14. The stock has seen a 16.2% decline over the past week and a 16.9% decline over...

Berkshire Hathaway (BRK.A) is in the spotlight after longtime CEO Warren Buffett stepped down, and successor Greg Abel moved toward exiting the conglomerate’s large Kraft Heinz position, signaling a possible new approach to capital deployment. See our latest analysis for Berkshire Hathaway. Abel’s early portfolio reshaping comes as Berkshire’s share price sits around US$714,000 after a 1 day share price return of 0.63% and a year to date share price return of a 4.05% decline, while the 5 year...

Operational updates put Ivanhoe Mines in focus Recent operational updates on production ramp up and plant optimization at Ivanhoe Mines (TSX:IVN) African copper operations have put the stock back on many investors’ radars, alongside ongoing questions around cash flow timing. See our latest analysis for Ivanhoe Mines. The latest operational news has come alongside a strong 90 day share price return of 33.57% and a 1 year total shareholder return of 15.25%. This suggests that momentum has...

Sun Hung Kai (SEHK:86) has been active on the funding side. It recently completed a tender offer for existing US dollar notes and issued new 6.75% guaranteed bonds due 2029 totaling $250 million. See our latest analysis for Sun Hung Kai. These funding moves come after a strong run in the shares, with a 9.5% 1 month share price return and a 13.47% 3 month share price return. The 1 year total shareholder return of 72.11% and 5 year total shareholder return of 104.88% point to momentum that has...

In recent commentary, Tennant reported that sales have effectively flatlined over the past two years, while earnings per share have fallen each year. This combination of stagnating revenue and shrinking profitability suggests Tennant may need to rethink how it drives both demand and margins. Next, we will examine how Tennant’s stagnating sales backdrop shapes the company’s broader investment narrative and potential growth story. Uncover the next big thing with financially sound penny...

Amkor Technology (AMKR) has been in focus after its latest quarterly report, where both revenue and earnings surpassed analyst estimates and prompted investors to reassess what the recent share price strength might be pricing in. See our latest analysis for Amkor Technology. Those results come after a strong run for the shares, with a 30 day share price return of 23.76% and a 90 day gain of 54.89%. The 1 year total shareholder return of 103.91% highlights how much sentiment around Amkor...

Axos Financial (AX) has drawn fresh attention after recent trading, with the stock last closing at $94.64. For investors, the current discussion centers on how its banking and securities mix aligns with recent returns. See our latest analysis for Axos Financial. Recent moves have been mixed, with a 1 day share price return of 3.03% and a 30 day share price return of 9.08%, while the 1 year total shareholder return of 35.92% and 5 year total shareholder return of 119.48% point to momentum that...

Siemens (XTRA:SIE) has extended its share buyback program, with the 102nd interim report confirming repurchases of 248,687 shares between 19 and 25 January 2026 as part of the initiative launched in February 2024. See our latest analysis for Siemens. The share buyback comes as Siemens shares trade at €255.95, with a 30-day share price return of 7.02% and a 1-year total shareholder return of 27.68%. Ongoing moves in industrial digitalization, Snowflake collaboration and data driven...

CTF Services (SEHK:659) is in focus after its insurance arm, CTF Life, released its first standalone ESG Disclosure Report. The report outlines plans around family wellness, ESG focused investing, and governance and risk management. See our latest analysis for CTF Services. The ESG report lands at a time when momentum in CTF Services' shares has been picking up, with a 1 month share price return of 21.20% and a 1 year total shareholder return of 53.23%. This suggests investors are reacting to...

CVB Financial (CVBF) just wrapped up a busy quarter, with fourth quarter and full year 2025 results topping Wall Street’s revenue and earnings expectations, alongside the completion of a previously announced share repurchase program. See our latest analysis for CVB Financial. Despite the latest quarter beating expectations and the completion of a US$80.4 million buyback covering 3.12% of shares, recent trading has been mixed, with a 6.21% 90 day share price return and a 1 year total...

Cimpress (CMPR) has put up a busy Q2 2026, with revenue at US$1.0 billion and basic EPS of US$2.01, alongside net income of US$49.3 million. The trailing twelve months show revenue of US$3.6 billion and EPS of US$0.95 tied to net income of US$23.4 million. The company has seen quarterly revenue move from US$939.2 million in Q2 2025 to US$1.0 billion in Q2 2026, while basic EPS has shifted from US$2.45 to US$2.01 over the same period. This sets up a picture where top line scale is being tested...

Sprott (TSX:SII) is drawing fresh attention after its Sprott Silver Miners & Physical Silver ETF, SLVR, crossed US$1b in assets under management and is offering concentrated exposure to silver miners and physical silver. See our latest analysis for Sprott. The milestone for SLVR comes as Sprott’s own shares have been volatile, with a 30.54% 30 day share price return and 52.61% 90 day share price return, alongside a very large 5 year total shareholder return that indicates long term holders...

Liquidia (LQDA) recently announced it will share interim and open label clinical data for LIQ861, branded as YUTREPIA, and investigational L606 at the PVRI 2026 Annual Congress, giving investors fresh detail on its pulmonary hypertension pipeline. See our latest analysis for Liquidia. The PVRI 2026 data update comes after a strong run in Liquidia’s share price, with a 30 day share price return of 25.07% and a 90 day share price return of 76.77%, while the 1 year total shareholder return is...

Are you wondering whether Metaplanet's share price reflects its true value, or if the story behind the stock is more complicated than the recent headlines suggest? Metaplanet's share price recently closed at ¥456, with returns of 12.6% over the last 30 days, a 7.0% decline over the past year and a very large gain over three years. Together, these figures may point to shifting views on its potential and risk. Recent news around Metaplanet has focused on its profile as a listed company and the...

BioNTech has started a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer. The company is moving further into oncology therapeutics beyond its vaccine portfolio. BioNTech appointed Kylie Jimenez as Chief People Officer to support its shift toward a multi-product oncology business. BioNTech, listed as NasdaqGS:BNTX, is trading at $116.77, with the share price up 22.6% over the past 30 days and 20.8% year to date. Returns over 1 year...

The Hartford Insurance Group reported past full-year 2025 results showing revenue of US$28.37 billion and net income of US$3.84 billion, both higher than the prior year. This earnings strength comes against a backdrop of generally steady analyst expectations before the release, highlighting how Hartford’s reported performance outpaced earlier cautious sentiment. Against this backdrop of stronger full-year earnings, we’ll now examine how Hartford’s higher revenue and profit shape its broader...

General Motors (NYSE:GM) recorded a $7.6b write down on its electric vehicle business and is restructuring its EV assets. The company is scaling back EV production plans and divesting certain EV assets in response to weaker demand and shifting policy conditions. GM is working with Ford and others to support a financial rescue for key supplier First Brands Group, which is in bankruptcy. The automaker is emphasizing higher margin software and subscription revenue, while increasing its dividend...

Halozyme Therapeutics (HALO) put fresh numbers on the table with updated 2025 revenue guidance of US$1.385b to US$1.40b and higher 2026 targets, tied to ENHANZE, new deals and recent acquisitions. See our latest analysis for Halozyme Therapeutics. The upbeat guidance and recent deals appear to be feeding into sentiment, with the share price at US$73.34 and a 30 day share price return of 8.33%, while the 1 year total shareholder return of 29.99% suggests momentum has been building over a...

In late January 2026, Anthropic introduced its “Cowork” AI task-management tool, intensifying competitive pressure on Atlassian’s core project and work-management products and prompting fresh scrutiny of its long-term positioning. This development highlights how rapidly AI-native entrants can challenge established software platforms, raising important questions about Atlassian’s product differentiation and customer stickiness as workflows become more automated. We’ll now examine how concerns...

With no single headline event driving Polaris (PII) today, investors are instead focusing on the stock’s recent returns and fundamentals, including revenue of US$7,236.3m and a reported net loss of US$465.5m. See our latest analysis for Polaris. Polaris shares trade at US$64.68 after a recent 7 day share price decline of 8.8%, while the 1 year total shareholder return of 39.3% contrasts with weaker 3 and 5 year total shareholder returns that point to fading longer term momentum. If Polaris...